Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer.

ABSTRACT: No consensus strategies exist for prognosticating metastatic castration-resistant prostate cancer (mCRPC). Circulating tumor DNA fraction (ctDNA%) is increasingly reported by commercial and laboratory tests but its utility for risk stratification is unclear. Here, we intersect ctDNA%, treatment outcomes, and clinical characteristics across 738 plasma samples from 491 male mCRPC patients from two randomized multicentre phase II trials and a prospective province-wide blood biobanking program. ctDNA% correlates with serum and radiographic metrics of disease burden and is highest in patients with liver metastases. ctDNA% strongly predicts overall survival, progression-free survival, and treatment response independent of therapeutic context and outperformed established prognostic clinical facto

SUBMITTER: Fonseca NM 

PROVIDER: S-EPMC10902374 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature